July 15, 2025
Currax Expands Access to FDA-Approved Obesity Treatment with Brand Name Contrave® with New Cash Price Available via GoodRx
Read moreMarch 20, 2025
Currax Secures Reliable and Consistent Supply of CONTRAVE®/MYSIMBA with FDA Approval for Second Manufacturing Site
Read moreMarch 11, 2025
Currax Pharmaceuticals: Peer-Reviewed Study in Obesity Pillars Further Substantiates Cardiovascular Safety Profile of CONTRAVE®/MYSIMBA®
Read moreFebruary 25, 2025
Currax Provides Update on Litigation Against Found Health Inc.
Read moreJanuary 10, 2025
Currax Announces Outstanding 2024 Financial and Operational Performance
Read moreJanuary 3, 2025
Currax Introduces First CONTRAVE® TV Ad and “Cravings Don’t Own Me” Campaign, Highlighting Food Cravings Management and Weight Loss
Read moreSeptember 24, 2024
Currax Pharmaceuticals Unveils New Disease Awareness Campaign to “Quiet the Food Noise,” a Key Barrier for Individuals Seeking Weight Loss
Read moreAugust 27, 2024
Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study
Read moreJuly 24, 2024
New Facility Assures Continuity of Supply of Anti-Obesity Treatment CONTRAVE®/MYSIMBA® Amidst GLP-1 Supply Issues
Read moreJanuary 25, 2024